| Marissa Nicole Visse, | |
|
100 Carmel Manor Dr, Fort Thomas, KY 41075-2300 | |
| (859) 781-5111 | |
| Not Available |
| Full Name | Marissa Nicole Visse |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 100 Carmel Manor Dr, Fort Thomas, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023658721 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 260002 (Kentucky) | Primary |
| Provider Name | Gms Therapy And Fitness Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1619634771 PECOS PAC ID: 0042603870 Enrollment ID: O20220131001408 |
News Archive
The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
A research review carried out by the HRB Centre for Primary Care Research, based in the Royal College of Surgeons in Ireland (RCSI) and published in this month's edition of the British Medical Journal (BMJ) has focused on how we can improve care and outcomes for patients with multimorbidity (co-existence of two or more long-terms health conditions in an individual).
InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company's Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce the pain and inflammation associated with ocular surgery.
Incidental chest computed tomography (CT) findings can help identify individuals at risk for future heart attacks and other cardiovascular events, according to a new study published online in the journal Radiology.
Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marissa Nicole Visse, 891 Kenton Station Rd, Alexandria, KY 41001-8042 Ph: (859) 240-0899 | Marissa Nicole Visse, 100 Carmel Manor Dr, Fort Thomas, KY 41075-2300 Ph: (859) 781-5111 |
News Archive
The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
A research review carried out by the HRB Centre for Primary Care Research, based in the Royal College of Surgeons in Ireland (RCSI) and published in this month's edition of the British Medical Journal (BMJ) has focused on how we can improve care and outcomes for patients with multimorbidity (co-existence of two or more long-terms health conditions in an individual).
InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company's Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce the pain and inflammation associated with ocular surgery.
Incidental chest computed tomography (CT) findings can help identify individuals at risk for future heart attacks and other cardiovascular events, according to a new study published online in the journal Radiology.
Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.
› Verified 2 days ago
Mackenzie Farmer, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 654 Highland Ave Ste 17, Fort Thomas, KY 41075 Phone: 859-441-0139 | |
Miss Mindy Lynn Ortlieb, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 85 N Grand Ave, Fort Thomas, KY 41075 Phone: 859-572-3120 | |
Kristin Mardis, MSOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Carmel Manor Dr, Fort Thomas, KY 41075 Phone: 859-781-5111 | |
Mrs. Valerie P Miller, M.S. OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 50 Southview Ave, Fort Thomas, KY 41075 Phone: 859-653-1762 | |
Courtney Schott, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Carmel Manor Dr, Fort Thomas, KY 41075 Phone: 419-206-7213 | |
Meredith Joan Klare, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 18 N Fort Thomas Ave Ste 302, Fort Thomas, KY 41075 Phone: 859-441-0139 |